Speed-up the Diagnosis and Evaluation of anoMalous Coronary ARTery From the Aorta
SMART
SMART: Speed-up the Diagnosis and Evaluation of anoMalous Coronary ARTery From the Aorta.
2 other identifiers
interventional
38
1 country
1
Brief Summary
Anomalous aortic origin of the coronary arteries (AAOCA) is a rare congenital disease and one of the leading causes of sudden cardiac deaths (SCD) in young athletes but also has a lethal presentation in adult age with myocardial infarction, even if not related to obstructive coronary arteries. Unfortunately, diagnostic imaging techniques, invasive assessment, and provocative stress tests have shown low sensitivity and specificity in detecting inducible ischemia, and a multimodality assessment is then necessary. Innovative tools have been developed in the medical field using computer-based simulation, 3-dimensional reconstruction, machine learning, and artificial intelligence (AI). With the application of such new technologies, we aim to fill the gap of knowledge and the diagnostic limitation regarding risk stratification for most subjects with AAOCA. This work seeks to enhance, fasten, and personalize the clinical diagnosis of AAOCA by integrating anatomical measurements, clinical data, and biomechanical patient-specific features. The SMART study will set a system to automatically segment and classify coronary arteries with AAOCA from computerized tomography angiography (CTA) by artificial intelligence (AI). Segmentation will feed a 3D model of the aortic root and coronary artery for biomechanical assessment through finite element analysis (FEA). This will allow us to assess the location of possible coronary artery compression under an effort condition. These in-silico results, the anatomical features measured by AI, and the clinical data will be integrated into a risk model to estimate the hazard risk of adverse events such as SCD or myocardial infarction. This workflow will be framed in an IT system to allow a web-based remote diagnostic service. Thanks to the proposed multidisciplinary approach, SMART aims to overcome the current diagnostic limitations related to the reduced ability of functional stress tests to detect ischemia. Potentially helping in patient-specific risk stratification, SMART is also thought to provide a way to get a first diagnostic indication about AAOCA being accessible from any hospital, fostering the diffusion of peripheral territorial support to the diagnosis and treatment of such rare disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 12, 2024
CompletedFirst Submitted
Initial submission to the registry
October 17, 2024
CompletedFirst Posted
Study publicly available on registry
November 26, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2027
April 15, 2026
March 1, 2026
1.9 years
October 17, 2024
April 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Analysis of Autonomic Test Data
Beat-to-beat series will be extracted from recorded signals to derive indices related to autonomic, cardiovascular, cerebrovascular, and peripheral microcirculation control during REST and STAND phases. The cardiac period will be defined as the interval between consecutive R peaks (RR- msec) in the ECG, with systolic (SAP - mmHg) and diastolic blood pressure (DAP - mmHg) calculated as the maximum and minimum pressures between these peaks. Random sequences of 250 beats will be selected from each recording and manually verified for corrections. Ectopic beats will be adjusted using cubic spline interpolation. Indices of cardiovascular control will be derived from time-domain variability measures, and spectral density will be estimated using a parametric autoregressive approach. Analyses will be conducted using software developed in Matlab and C++.
two years
Study Arms (1)
Prospective study
EXPERIMENTALThe prospective phase aims to validate the entire model developed during the retrospective phase and to evaluate the role of autonomic response in subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA). The prospective recruitment of the cohort of AAOCA patients for autonomic assessment and validation will span the entire duration of the study. Our objective is to recruit 38 patients with AAOCA to obtain consistent and uniform data from at least 32 participants. Patients in this cohort will undergo an active standing test to elicit an autonomic response, and the results will be compared with reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions.
Interventions
Autonomic regulation sub-analysis: Autonomic control will be evaluated in a population prospectively recruited. Thirty-eight subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA) will undergo an active standing test. For this prospective sample, demographic and clinical data, as well as DICOM images from previously conducted diagnostic CT angiographies (CTAs) for AAOCA, will also be collected. These data will be utilized to assess the final functionality of the online platform before its public launch. The patients will be subjected to the active standing test to elicit an autonomic response, with results compared to reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions.
Eligibility Criteria
You may qualify if:
- Adult and pediatric patients (age \> 6 years) with anomalous coronary origin from the aorta (AAOCA).
- Patients in spontaneous sinus rhythm.
- Signed informed consent.
You may not qualify if:
- Patients with acute and chronic inflammatory conditions such as chronic liver disease, chronic kidney failure (creatinine \> 1.5 mg/dl), and thyroid disorders.
- Patients with arrhythmias, absence of sinus rhythm.
- Contraindications to autonomic testing.
- Patients with a known allergy to materials in recording devices.
- Female patients who are pregnant.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- IRCCS Policlinico S. Donatolead
- University of Paviacollaborator
- University of Naplescollaborator
- The Mediterranean Institute for Transplantation and Advanced Specialized Therapiescollaborator
Study Sites (1)
IRCCS Policlinico San Donato
San Donato Milanese, Italia, 20097, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 17, 2024
First Posted
November 26, 2024
Study Start
September 12, 2024
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
February 1, 2027
Last Updated
April 15, 2026
Record last verified: 2026-03